Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from Celgene Corporation; Kite Pharma, Inc; and Legend Biotech USA Inc.

Community Practice Connections™: Advancing CAR T-Cell Therapies in Oncology Care

Release Date: April 30, 2020
Expiration Date: April 30, 2021

Activity Overview

Community Practice Connections™: Advancing CAR T-Cell Therapies in Oncology Care consists of a series of interactive clinical vignettes, short video interviews with leading experts in hematologic malignancies, and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes and questions commonly faced in the community oncology practice setting.

Benefits of Participating

  • Discuss the unique properties of chimeric antigen receptor (CAR T)–cell therapy
  • Learn about current and upcoming indications for CAR T cells in patients with hematologic malignancies
  • Read about the importance of long-term monitoring of patients after CAR T-cell infusion

Acknowledgement of Support

This activity is supported by educational grants from Celgene Corporation; Kite Pharma, Inc; and Legend Biotech USA Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward community-based hematologists and medical oncologists, as well as fellows involved in the treatment and management of patients with hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of hematologic malignancies may also participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Analyze the mechanistic properties of CAR T-cell therapies, including design characteristics that impact efficacy and safety
  • Evaluate clinical trial data regarding applications of CAR T-cell therapy in hematologic malignancy management
  • Summarize the role of CAR-T cells in oncology across existing indications and potential future indications
  • Categorize best practices in adverse event monitoring and management for patients receiving CAR T-cell therapy

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Andre Goy, MD
Andre Goy, MD
Chairman and Executive Director
Lymphoma Division Chief, John Theurer Cancer Center
Chief Science Officer
Regional Cancer Care Associates
Lydia Pfund Chair for Lymphoma
Professor of Medicine, Georgetown University
Professor and Chair, Department of Oncology – Hackensack Meridian School of Medicine at Seton Hall University
Hackensack, NJ

Disclosures: Grant Research Support: PI research through institution: Acerta Pharma; AstraZeneca; Bayer; Cancer and Leukemia Group B; Celgene Corporation; Constellation Pharmaceuticals; F. Hoffman-La Roche, Ltd; Genentech; Janssen Pharmaceuticals; Kite Pharma; MorphoSys AG; Pharmacyclics LLC. Consultant: Acerta Pharma; Celgene Corporation; Kite Pharma/Gilead Sciences, Inc. Other: Advisory Board: Janssen Pharmaceuticals; Kite Pharma/Gilead Sciences, Inc. Board Member: COTA Inc. Steering Committee: AstraZeneca. Honoraria: Acerta Pharma; AstraZeneca; Celgene Corporation; Janssen Pharmaceuticals; Kite Pharma/Gilead Sciences, Inc.

Jae H. Park, MD
Jae H. Park, MD
Associate Attending Physician
Department of Medicine, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Consultant: Novartis, Kite Pharma, Allogene.

Noopur Raje, MD
Noopur Raje, MD
Professor of Medicine
Harvard Medical School
Director, Center for Multiple Myeloma
Massachusetts General Hospital
Boston, MA

Disclosures: Grant Research Support: AstraZeneca; Consultant: Amgen, Inc; Bristol Myers Squibb; Celgene Corporation; Janssen Pharmaceuticals; Juno Therapeutics; Merck; Takeda Pharmaceutical Co Ltd.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By